US FDA gives green light for use of AstraZeneca's Voydeya

America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

AstraZeneca

10,292.00p

16:49 14/11/24

1.46%

148.00p

FTSE 100

8,071.19

16:49 14/11/24

n/a

FTSE 350

4,459.02

16:38 14/11/24

n/a

FTSE All-Share

4,417.25

16:54 14/11/24

n/a

Pharmaceuticals & Biotechnology

19,794.96

16:38 14/11/24

0.96%

187.95

PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH is the condition in which red blood cells outside of blood vessels were destroyed.

Voydeya could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

The drug was a first-in-class, oral, Factor D inhibitor meant to address the needs of the roughly 10-20% of patients with PNH experiencing "clinically significant" EVH when they were being treated with a C5 inhibitor.